CoChat

Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF

Open access
Weyer, Karin, Mirzayev, Fuad, Migliori, Giovanni Battista, Van Gemert, Wayne, D'Ambrosio, Lia, Zignol, Matteo, Floyd, Katherine, Centis, Rosella, Cirillo, Daniela M., Tortoli, Enrico, Gilpin, Chris, de Dieu Iragena, Jean, Falzon, Dennis, Raviglione, Mario · 2013 · European Respiratory Journal

The DOI matches its Crossref record; 136 of the 137 references it cites were found in a registry or an index.

Abstract

If tuberculosis (TB) is to be eliminated as a global health problem in the foreseeable future, improved detection of patients, earlier diagnosis and timely identification of rifampicin resistance will be critical. New diagnostics released in recent years have improved this perspective but they require investments in laboratory infrastructure, biosafety and staff specialisation beyond the means of many resource-constrained settings where most patients live. Xpert MTB/RIF, a new assay employing automated nucleic acid amplification to detect Mycobacterium tuberculosis , as well as mutations that confer rifampicin resistance, holds the promise to largely overcome these operational challenges. In this article we position Xpert MTB/RIF in today’s TB diagnostic landscape and describe its additional potential as an adjunct to surveillance and surveys, taking into account considerations of pricing and ethics. In what could serve as a model for the future formulation of new policy on diagnostics, we trace the unique process by which the World Health Organization consulted international expertise and systematically assessed published evidence and freshly emerging experience from the field ahead of its endorsement of the Xpert MTB/RIF technology in 2010, summarise subsequent research findings and guidance on who to test and how, and provide perspectives on scaling up the new technology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1183/09031936.00157212

Cites

136 of 136 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 The GeneXpert system (personal communication; Foundation for Innovative New Diagnostics, Geneva, Switzerland).
FIGURE 1 The GeneXpert system (personal communication; Foundation for Innovative New Diagnostics, Geneva, Switzerland).CC-BY-NC · From the PDF
FIGURE 2 The step-by-step Xpert MTB/RIF assay process. SR: sterilising reagent. Reproduced from [6] with permission from the publisher.
FIGURE 2 The step-by-step Xpert MTB/RIF assay process. SR: sterilising reagent. Reproduced from [6] with permission from the publisher.CC-BY-NC · From the PDF
FIGURE 3 The World Health Organization (WHO) policy development process for tuberculosis (TB) diagnostics. GRADE: Grades of Recommendations Assessment, Development and Evaluation; QUADAS: Quality Assessment of Diagnostic Accuracy Studies; STAG-TB: Strategic and Technical Advisory Group for Tuberculosis.
FIGURE 3 The World Health Organization (WHO) policy development process for tuberculosis (TB) diagnostics. GRADE: Grades of Recommendations Assessment, Development and Evaluation; QUADAS: Quality Assessment of Diagnostic Accuracy Studies; STAG-TB: Strategic and Technical Advisory Group for Tuberculosis.CC-BY-NC · From the PDF
FIGURE 4 Global uptake of Xpert MTB/RIF up to June 30, 2012. As of June 30, 2012, a total of 749 GeneXpert instruments (comprising 3602 modules) and 1107330 Xpert MTB/ RIF cartridges had been procured in the public sector in 67 of the 145 countries eligible for concessional pricing. Reproduced from [6] with permission from the publisher.
FIGURE 4 Global uptake of Xpert MTB/RIF up to June 30, 2012. As of June 30, 2012, a total of 749 GeneXpert instruments (comprising 3602 modules) and 1107330 Xpert MTB/ RIF cartridges had been procured in the public sector in 67 of the 145 countries eligible for concessional pricing. Reproduced from [6] with permission from the publisher.CC-BY-NC · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 136 references

Research works printed but not linked: 1

  1. 10.1016/S0140-6736(11)61242-7 · DOI

Cited by

See all 256

Metadata

Authors
Weyer, K., Mirzayev, F., Migliori, G. B., Van Gemert, W., D'Ambrosio, L., Zignol, M., Floyd, K., Centis, R., Cirillo, D. M., Tortoli, E., Gilpin, C., de Dieu Iragena, J., Falzon, D., & Raviglione, M.
Affiliations
  • World Health Organization (CH)
  • Fondazione Salvatore Maugeri (IT)
  • IRCCS San Raffaele Roma (IT)
Venue
European Respiratory Journal
Published
2012-11-22
Volume
42
Issue
1
Pages
252-271
ISSN
  • 0903-1936 (ISSN-L)
  • 1399-3003
OpenAlex
W2132406189
Cited by
256
References
137
Citations by year
2026: 3 · 2025: 7 · 2024: 14 · 2023: 6 · 2022: 5 · 2021: 16 · 2020: 10 · 2019: 21 · 2018: 17 · 2017: 25 · 2016: 28 · 2015: 33 · 2014: 40 · 2013: 30
FWCI
4.09
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • European Respiratory Journal (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
  • Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
  • Health Sciences › Medicine › Epidemiology › Mycobacterium research and diagnosis
Keywords
Xpert MTB/RIF, tuberculosis diagnosis, rifampicin resistance, Mycobacterium tuberculosis, tuberculosis elimination, resource-limited settings, tuberculosis surveillance, rapid molecular diagnostics
MeSH terms
Cost-Benefit Analysis, Drug Resistance, Health Policy, Humans, Mycobacterium tuberculosis, Predictive Value of Tests, Sputum, Tuberculosis, Pulmonary, World Health Organization, Reproducibility of Results, Prevalence, Polymerase Chain Reaction, Tuberculosis, Multidrug-Resistant, Nucleic Acid Amplification Techniques, Molecular Diagnostic Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. https://app.cochat.ai/papers/10.1183/09031936.00157212
The paper
Weyer, K., Mirzayev, F., Migliori, G. B., Van Gemert, W., D'Ambrosio, L., Zignol, M., Floyd, K., Centis, R., Cirillo, D. M., Tortoli, E., Gilpin, C., de Dieu Iragena, J., Falzon, D., & Raviglione, M. (2013). Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. European Respiratory Journal. https://doi.org/10.1183/09031936.00157212

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.